Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Summary: Acute myeloid leukemia (AML) is a tough type of blood cancer. Sometimes, doctors use a targeted drug called sorafenib to help treat it, especially for patients with a specific gene change (FLT3-ITD) who are getting a stem cell transplant. This study looked at whether sorafenib helped these patients live longer. Overall, the drug didn't make a big difference for everyone. But, for patients whose cancer had come back or wasn't responding to standard treatment, sorafenib was a game-changer. It significantly improved their chances of survival and kept the cancer away longer. So, while it's not a magic bullet for everyone, it's a promising treatment for those fighting stubborn, relapsed leukemia.